Carib A. Oquendo

Array ( [id] => 16198644 [patent_doc_number] => 10723794 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-28 [patent_title] => Anti-CcL8 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/371386 [patent_app_country] => US [patent_app_date] => 2019-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 21 [patent_no_of_words] => 8401 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16371386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14929953 [patent_doc_number] => 20190300614 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/362962 [patent_app_country] => US [patent_app_date] => 2019-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24305 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16362962 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16582881 [patent_doc_number] => 20210017283 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => Antibodies Binding to Vista at Acidic pH [patent_app_type] => utility [patent_app_number] => 16/982277 [patent_app_country] => US [patent_app_date] => 2019-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 99699 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -190 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16982277 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17784711 [patent_doc_number] => 11407823 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-09 [patent_title] => Treatment of cancer with anti-LAP monoclonal antibodies [patent_app_type] => utility [patent_app_number] => 16/355544 [patent_app_country] => US [patent_app_date] => 2019-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 67 [patent_figures_cnt] => 100 [patent_no_of_words] => 48123 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 246 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16355544 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14534567 [patent_doc_number] => 20190202905 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => ANTIBODIES TO M-CSF [patent_app_type] => utility [patent_app_number] => 16/354615 [patent_app_country] => US [patent_app_date] => 2019-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33211 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16354615 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15345303 [patent_doc_number] => 20200010543 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-09 [patent_title] => METHODS TO MANIPULATE ALPHA-FETOPROTEIN (AFP) [patent_app_type] => utility [patent_app_number] => 16/284005 [patent_app_country] => US [patent_app_date] => 2019-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29839 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16284005 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17975566 [patent_doc_number] => 11492414 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-08 [patent_title] => ERG monoclonal antibodies [patent_app_type] => utility [patent_app_number] => 16/277687 [patent_app_country] => US [patent_app_date] => 2019-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 29 [patent_no_of_words] => 19320 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16277687 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14406881 [patent_doc_number] => 20190169284 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-06 [patent_title] => SOLUBILITY OPTIMIZATION OF IMMUNOBINDERS [patent_app_type] => utility [patent_app_number] => 16/267460 [patent_app_country] => US [patent_app_date] => 2019-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11543 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16267460 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14685123 [patent_doc_number] => 20190241676 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => ANTI-MERTK AGONISTIC ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/256737 [patent_app_country] => US [patent_app_date] => 2019-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42450 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16256737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14883581 [patent_doc_number] => 10421817 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2019-09-24 [patent_title] => Antibodies binding human Claudin 18.2 and uses thereof [patent_app_type] => utility [patent_app_number] => 16/254587 [patent_app_country] => US [patent_app_date] => 2019-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 41 [patent_no_of_words] => 19652 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 296 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16254587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15178251 [patent_doc_number] => 20190359717 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => ANTI-cMET ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/239829 [patent_app_country] => US [patent_app_date] => 2019-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24115 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16239829 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15180873 [patent_doc_number] => 20190361028 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => FREE NGAL AS A BIOMARKER FOR CANCER [patent_app_type] => utility [patent_app_number] => 16/238940 [patent_app_country] => US [patent_app_date] => 2019-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9535 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16238940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14868075 [patent_doc_number] => 20190284279 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => BISPECIFIC ANTIBODY BINDING TO HUMAN CD19 AND CD3 [patent_app_type] => utility [patent_app_number] => 16/237124 [patent_app_country] => US [patent_app_date] => 2018-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14719 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16237124 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17156153 [patent_doc_number] => 20210317204 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => BI-SPECIFIC BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 16/957079 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30995 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -66 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16957079 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16688370 [patent_doc_number] => 20210070846 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => SPECIFIC DOSAGE REGIMEN FOR HEMIBODY THERAPY [patent_app_type] => utility [patent_app_number] => 16/955902 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6221 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16955902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17681020 [patent_doc_number] => 11365259 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-21 [patent_title] => IGF-1R antibody and its use as addressing vehicle for the treatment of cancer [patent_app_type] => utility [patent_app_number] => 16/223363 [patent_app_country] => US [patent_app_date] => 2018-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 50 [patent_no_of_words] => 32275 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16223363 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14746839 [patent_doc_number] => 20190256593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => CD33 BINDING AGENTS [patent_app_type] => utility [patent_app_number] => 16/221811 [patent_app_country] => US [patent_app_date] => 2018-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16876 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16221811 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16506184 [patent_doc_number] => 20200385440 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => MODIFIED BISPECIFIC T CELL RECEPTORS [patent_app_type] => utility [patent_app_number] => 16/769538 [patent_app_country] => US [patent_app_date] => 2018-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39686 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -89 [patent_words_short_claim] => 187 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16769538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16438367 [patent_doc_number] => 20200355693 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => A NEW MARKER FOR PREDICTING THE SENSITIVITY TO PI3K INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/765345 [patent_app_country] => US [patent_app_date] => 2018-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10730 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16765345 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14069467 [patent_doc_number] => 20190083621 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => RS7 Antibodies [patent_app_type] => utility [patent_app_number] => 16/198276 [patent_app_country] => US [patent_app_date] => 2018-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23135 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16198276 [rel_patent_id] =>[rel_patent_doc_number] =>)